Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia [0.03%]
共价BTKi治疗失败后的补救治疗：在Waldenström巨球蛋白血症临床实践中未被满足的需求
Anna Maria Frustaci,Arianna Zappaterra,Andrea Galitzia et al.
Anna Maria Frustaci et al.
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry [0.03%]
使用抗CD19 CAR-T细胞治疗复发或难治性原发纵隔B细胞淋巴瘤患者的疗效：来自法国国家DESCAR-T注册研究的CARTHYM研究
Jean Galtier,Charles Mesguich,Pierre Sesques et al.
Jean Galtier et al.
Primary mediastinal B-cell lymphoma (PMBL) is often cured with dose-dense anthracycline-based regimens but the prognosis at relapse or progression remains poor. While anti-CD19 CAR-T cell therapy has dramatically improved outcomes in relaps...
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation [0.03%]
异基因造血干细胞移植后供者淋巴细胞输注的HLA进化差异分值
Sophie Le Grand,Juliette Villemonteix,Etienne Daguindau et al.
Sophie Le Grand et al.
Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life-threatening toxicities such as graft versus host disease (GVH...
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS [0.03%]
Luspatercept的治疗反应可预测并改善LR-MDS患者的真实世界治疗结局及总生存期
Angela Consagra,Luca Lanino,Najla H Al Ali et al.
Angela Consagra et al.
We explored the impact of luspatercept therapy on overall survival (OS) and possible predictors of response in low-risk (LR) myelodysplastic syndrome (MDS) patients. We evaluated 331 anemic patients treated with luspatercept. Hematological ...
Single-cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment [0.03%]
高超二倍体急性淋巴细胞白血病初治和治疗过程中的单细胞DNA及表面蛋白特征分析
Margo Aertgeerts,Sarah Meyers,Olga Gielen et al.
Margo Aertgeerts et al.
High hyperdiploid (HeH) B-cell acute lymphoblastic leukemia (B-ALL) is the most prevalent subtype of childhood ALL. This leukemia is characterized by trisomies and tetrasomies of specific chromosomes and additional point mutations. Here, we...
Valentine Brousse,David Rees,Raffaella Colombatti
Valentine Brousse
Editorial
HemaSphere. 2025 Feb 6;9(2):e70082. DOI:10.1002/hem3.70082 2025
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study [0.03%]
嵌合抗原受体T细胞治疗T细胞/巨噬细胞增生性大B细胞淋巴瘤的疗效及其疾病进展后的后续治疗策略：GELTAMO/GETH研究
Mariana Bastos-Oreiro,Gloria Iacoboni,Víctor N Garcés et al.
Mariana Bastos-Oreiro et al.
Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure [0.03%]
化疗压力下TCF3-PBX1白血病单细胞水平的动态演变规律研究
Mira Kusterer,Mari Lahnalampi,Minna Voutilainen et al.
Mira Kusterer et al.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. The translocation t(1;19), encoding the TCF3-PBX1 fusion, is associated with intermediate risk and central nervous system (CNS) infiltration at relapse. Using our previ...
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry [0.03%]
初诊即伴有血细胞减少症的原发性骨髓纤维化患者结局分析——ERNEST-2真实世界前瞻性注册研究
Paola Guglielmelli,Arianna Ghirardi,Alessandra Carobbio et al.
Paola Guglielmelli et al.
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies [0.03%]
2022年WHO和ICC分类下的AML诊断与治疗：分歧的命名法在常见治疗中汇聚
Uwe Platzbecker,Richard A Larson,Sandeep Gurbuxani
Uwe Platzbecker
As a consequence of rapidly developing genetic technologies and advances in the understanding of the pathogenesis of acute myeloid leukemia (AML), the classification of AML has moved gradually from a morphologic and cytochemical-based syste...